These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21435247)

  • 1. Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?
    Lexchin J
    BMC Health Serv Res; 2011 Mar; 11():64. PubMed ID: 21435247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property.
    Bian H; McCourt C
    Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25573772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
    Hollis A
    Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
    [No Abstract]   [Full Text] [Related]  

  • 5. Canada ordered to implement WTO ruling against "stockpiling" of generic drugs.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2000; 5(4):27. PubMed ID: 11833161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?
    Lexchin J
    Int J Health Serv; 2005; 35(2):237-56. PubMed ID: 15932005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixed WTO ruling on generic drug development.
    Elliott R
    Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):38-42, 40-4. PubMed ID: 11833195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
    Son KB; Lopert R; Gleeson D; Lee TJ
    Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
    Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors.
    Laeeque H; Boon H; Kachan N; Cohen JC; D'Cruz J
    BMC Health Serv Res; 2006 May; 6():63. PubMed ID: 16734916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent dispute: Delhi High Court gives a boost to access to affordable medicines.
    Menghaney L
    Indian J Med Ethics; 2010; 7(2):97-100. PubMed ID: 20432882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 18. Canada's laws on pharmaceutical intellectual property: the case for fundamental reform.
    Grootendorst P; Bouchard R; Hollis A
    CMAJ; 2012 Mar; 184(5):543-9. PubMed ID: 22065362
    [No Abstract]   [Full Text] [Related]  

  • 19. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
    Burshtein S
    Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
    [No Abstract]   [Full Text] [Related]  

  • 20. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
    Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
    Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.